Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
No Thumbnail Available
Date
2020-08-05
Authors
Usman, S.O.
Oreagba, I.A
Akinyede, A.A.
Agbaje, E.O.
Akinleye, M.O.
Onwujuobi, A.G.
Ken-Owotor, C.
Adeuja, O.
Ogunfowokan, T.
Kogbe, S.
Journal Title
Journal ISSN
Volume Title
Publisher
Science Direct
Abstract
Patients living with HIV in malarial endemic regions may experience clinically significant drug interaction between antiretroviral and antimalarial drugs. Effects of nevirapine (NVP), efavirenz (EFV) and lopinavir/ritonavir (LPVr) on lumefantrine (LM) therapeutic concentrations and toxicity were evaluated. In a four-arm parallel study design, the blood samples of 40 participants, treated with artemether/ lumefantrine (AL), were analysed. Lumefantrine Cmax was increased by 32% (p ¼ 0.012) and 325% (p < 0.0001) in the NVP and LPVr arms respectively but decreased by 62% (p < 0.0001) in the EFV-arm. AUC of LM was, respectively, increased by 50% (p ¼ 0.27) and 328% (p < 0.0001) in the NVP and LPVr arms but decreased in the EFV-arm by 30% (p ¼ 0.019). Median day 7 LM concentration was less than 280 ng/
mL in EFV-arm (239 ng/mL) but higher in control (290 ng/mL), NVP (369 ng/mL, p ¼ 0.004) and LPVr (1331 ng/mL, p < 0.0001) arms. There were no clinically relevant toxicities nor adverse events in both control and test arms. Artemether/lumefantrine is safe and effective for treatment of malaria in PLWHA taking NVP and LPVr based ART regimen but not EFV-based regimen.
Description
Keywords
Lumefantrine , Antiretroviral drugs , Therapeutic concentrations , Malaria , HIV
Citation
Usman, S. O., Oreagba, I. A., Akinyede, A. A., Agbaje, E. O., Akinleye, M. O., Onwujuobi, A. G., ... & Akanmu, A. S. (2020). Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. Journal of Pharmacological Sciences, 144(3), 95-101.